Literature DB >> 26747009

Current drug therapy and pharmaceutical challenges for Chagas disease.

José Bermudez1, Carolina Davies2, Analía Simonazzi1, Juan Pablo Real3, Santiago Palma4.   

Abstract

One of the most significant health problems in the American continent in terms of human health, and socioeconomic impact is Chagas disease, caused by the protozoan parasite Trypanosoma cruzi. Infection was originally transmitted by reduviid insects, congenitally from mother to fetus, and by oral ingestion in sylvatic/rural environments, but blood transfusions, organ transplants, laboratory accidents, and sharing of contaminated syringes also contribute to modern day transmission. Likewise, Chagas disease used to be endemic from Northern Mexico to Argentina, but migrations have earned it global. The parasite has a complex life cycle, infecting different species, and invading a variety of cells - including muscle and nerve cells of the heart and gastrointestinal tract - in the mammalian host. Human infection outcome is a potentially fatal cardiomyopathy, and gastrointestinal tract lesions. In absence of a vaccine, vector control and treatment of patients are the only tools to control the disease. Unfortunately, the only drugs now available for Chagas' disease, Nifurtimox and Benznidazole, are relatively toxic for adult patients, and require prolonged administration. Benznidazole is the first choice for Chagas disease treatment due to its lower side effects than Nifurtimox. However, different strategies are being sought to overcome Benznidazole's toxicity including shorter or intermittent administration schedules-either alone or in combination with other drugs. In addition, a long list of compounds has shown trypanocidal activity, ranging from natural products to specially designed molecules, re-purposing drugs commercialized to treat other maladies, and homeopathy. In the present review, we will briefly summarize the upturns of current treatment of Chagas disease, discuss the increment on research and scientific publications about this topic, and give an overview of the state-of-the-art research aiming to produce an alternative medication to treat T. cruzi infection.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benznidazol; Chagas disease; New medication; Nifurtimox; Trypanocidal treatment; Trypanosoma cruzi

Mesh:

Substances:

Year:  2015        PMID: 26747009     DOI: 10.1016/j.actatropica.2015.12.017

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  49 in total

1.  Lychnopholide in Poly(d,l-Lactide)-Block-Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi Strain at Acute and Chronic Phases.

Authors:  Renata Tupinambá Branquinho; Carlos Geraldo Campos de Mello; Maykon Tavares Oliveira; Levi Eduardo Soares Reis; Paula Mello de Abreu Vieira; Dênia Antunes Saúde-Guimarães; Vanessa Carla Furtado Mosqueira; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  A new chemotype with promise against Trypanosoma cruzi.

Authors:  Xiaofang Wang; Monica Cal; Marcel Kaiser; Frederick S Buckner; Galina I Lepesheva; Austin G Sanford; Alexander I Wallick; Paul H Davis; Jonathan L Vennerstrom
Journal:  Bioorg Med Chem Lett       Date:  2019-10-31       Impact factor: 2.823

3.  Pep5, a Fragment of Cyclin D2, Shows Antiparasitic Effects in Different Stages of the Trypanosoma cruzi Life Cycle and Blocks Parasite Infectivity.

Authors:  Christiane Bezerra de Araujo; Loyze Paola de Lima; Simone Guedes Calderano; Flávia Silva Damasceno; Ariel M Silber; Maria Carolina Elias
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease.

Authors:  Julianna Siciliano de Araújo; Alfonso García-Rubia; Victor Sebastián-Pérez; Titilola D Kalejaiye; Patrícia Bernardino da Silva; Cristina Rosa Fonseca-Berzal; Louis Maes; Harry P De Koning; Maria de Nazaré Correia Soeiro; Carmen Gil
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Determination of Benznidazole in Human Dried Blood Spots by Liquid Chromatography-Mass Spectrometry to Monitor Adherence to Trypanosoma cruzi Infection Treatment in Infants and Children.

Authors:  Jeremiah D Momper; Nathan J Hanan; Steven S Rossi; Mark H Mirochnick; Maria Luisa Cafferata; Antonia Lavenia; Isolina Flores; Luz Gibbons; Alvaro Ciganda; Sergio Sosa Estani; Edmund V Capparelli; Pierre Buekens
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

6.  Plants of Brazilian restingas with tripanocide activity against Trypanosoma cruzi strains.

Authors:  Robson Xavier Faria; André Luis Almeida Souza; Barbara Lima; Luis Armando Candido Tietbohl; Caio Pinho Fernandes; Raquel Rodrigues Amaral; Bettina Monika Ruppelt; Marcelo Guerra Santos; Leandro Rocha
Journal:  J Bioenerg Biomembr       Date:  2017-11-17       Impact factor: 2.945

7.  Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.

Authors:  Matthew O Wiens; Steve Kanters; Edward Mills; Alejandro A Peregrina Lucano; Silvia Gold; Dieter Ayers; Luis Ferrero; Alejandro Krolewiecki
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 8.  Artemisinin and its derivatives in treating protozoan infections beyond malaria.

Authors:  Cecilia Shi Ni Loo; Nelson Siu Kei Lam; Deying Yu; Xin-Zhuan Su; Fangli Lu
Journal:  Pharmacol Res       Date:  2016-11-17       Impact factor: 7.658

9.  Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells.

Authors:  Quhuan Li; Qun Lin; Zhong Yun
Journal:  Cancer Biol Ther       Date:  2016-10-27       Impact factor: 4.742

10.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.